Page 1

August 16 , 2021 Ra Medical SYSTEMS Ra Medical Systems Reports 2021 Second Quarter Financial Results Conference call begins at 4:30 p.m. Eastern time today CARLSBAD , Calif .-- ( BUSINESS WIRE ) -- Ra Medical Systems , Inc. ( NYSE American : RMED ) , a medical device company focusing on commercializing its excimer laser system to treat vascular disease , reports financial results for the three and six months ended June 30 , 2021 and provides a business update . Recent Operational Highlights • Announced the sale of the Pharos dermatology business as part of the continued focus by the company of its resources on the large peripheral artery disease ( PAD ) market • Enrolled 20 additional subjects in the company's atherectomy pivotal clinical study since early May , for a total of 70 subjects enrolled to date in the 100 - subject study • Continued progress on catheter engineering projects including a hands - on workshop with interventional physicians to test guidewire compatible prototype devices • Conducted early , promising research demonstrating the ability to use the DABRA system to fracture calcium in arteries Earlier today we announced the ale our Pharos dermatology business following an extensive review and evaluation of strategic options . We believe this decision provides the best pathway to building shareholder value by allowing Ra Medical to continue to focus our resources on the large and growing market for medical devices to treat PAD . An estimated 19 million to 21 million people in the U.S. have PAD and the market segments we are targeting are projected to exceed $ 900 million in revenue this year , " said Will McGuire , Ra Medical CEO . " We have reduced our expense structure going forward while improving our financial position as a result of the net proceeds received from the transaction and our At - the - Market offerings , " he added . “ We are also exploring the potential for our DABRA technology to create shock waves that can fracture arterial calcium , sometimes referred to as intravascular lithotripsy . This application of our technology represents an exciting potential growth opportunity to treat calcified vessels in the PAD and coronary artery disease markets . " Second Quarter Financial Highlights Net revenue for the second quarter of 2021 was $ 1.0 million , which consisted of product sales of $ 0.3 million and service and other revenue of $ 0.7 million . This compares with net revenue of $ 0.9 million for the second quarter of 2020 , which consisted of product sales of $ 0.2 million and service and other revenue of $ 0.7 million .